Source:http://linkedlifedata.com/resource/pubmed/id/11522497
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2001-8-27
|
pubmed:abstractText |
The aim of the present study was to elucidate the long-term effect of epalrestat, an aldose reductase inhibitor (ARI), on renal function in patients with type 2 diabetes mellitus showing microalbuminuria. Patients were allocated to two groups (cases and controls) matched for age, BMI, and the extent of urinary albumin excretion (UAE). Thirty-five type 2 diabetic patients presenting microalbuminuria were included in this study: cases were treated with epalrestat (150 mg/day) for 5 years. No significant changes were found in blood pressure, HbA1c, and total cholesterol in either group during the observation period. In the control group, UAE increased significantly (P<.01) from 82+/-12 mg/g Cr at the baseline to 301+/-111 mg/g Cr at the end of the study, while UAE remained unchanged, 81+/-15 mg/g Cr at the baseline and 87+/-19 mg/g Cr at the end of the study, in the epalrestat-treated group. Reciprocal creatinine measured by an enzyme assay decreased significantly (P<.01) in both groups; however, the reduction rate in the epalrestat-treated group was significantly (P<.05) smaller than that in the control group. These results suggest the potential usefulness of ARIs in preventing the progression of incipient diabetic nephropathy in patients with type 2 diabetes mellitus.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aldehyde Reductase,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/ONO 2235,
http://linkedlifedata.com/resource/pubmed/chemical/Rhodanine,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidines
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1056-8727
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
241-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11522497-Albuminuria,
pubmed-meshheading:11522497-Aldehyde Reductase,
pubmed-meshheading:11522497-Case-Control Studies,
pubmed-meshheading:11522497-Creatinine,
pubmed-meshheading:11522497-Diabetes Mellitus, Type 2,
pubmed-meshheading:11522497-Diabetic Nephropathies,
pubmed-meshheading:11522497-Enzyme Inhibitors,
pubmed-meshheading:11522497-Female,
pubmed-meshheading:11522497-Humans,
pubmed-meshheading:11522497-Male,
pubmed-meshheading:11522497-Middle Aged,
pubmed-meshheading:11522497-Reference Values,
pubmed-meshheading:11522497-Rhodanine,
pubmed-meshheading:11522497-Thiazolidines,
pubmed-meshheading:11522497-Time Factors
|
pubmed:articleTitle |
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
|
pubmed:affiliation |
Second Department of Internal Medicine, Toho University, School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan.
|
pubmed:publicationType |
Journal Article
|